DE60001271T2 - Hydroxymatairesinol in der krebs-prevention - Google Patents

Hydroxymatairesinol in der krebs-prevention

Info

Publication number
DE60001271T2
DE60001271T2 DE60001271T DE60001271T DE60001271T2 DE 60001271 T2 DE60001271 T2 DE 60001271T2 DE 60001271 T DE60001271 T DE 60001271T DE 60001271 T DE60001271 T DE 60001271T DE 60001271 T2 DE60001271 T2 DE 60001271T2
Authority
DE
Germany
Prior art keywords
hydroxymatairesinol
person
cancer
prevention
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60001271T
Other languages
English (en)
Other versions
DE60001271D1 (de
Inventor
Markku Ahotupa
Christer Eckerman
Lauri Kangas
Sari Maekelae
Niina Saarinen
Risto Santti
Anni Waerri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hormos Nutraceutical Ltd Oy
Original Assignee
Hormos Nutraceutical Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Nutraceutical Ltd Oy filed Critical Hormos Nutraceutical Ltd Oy
Application granted granted Critical
Publication of DE60001271D1 publication Critical patent/DE60001271D1/de
Publication of DE60001271T2 publication Critical patent/DE60001271T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60001271T 1999-03-30 2000-03-09 Hydroxymatairesinol in der krebs-prevention Expired - Lifetime DE60001271T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/281,094 US6451849B1 (en) 1999-03-30 1999-03-30 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
PCT/FI2000/000181 WO2000059946A1 (en) 1999-03-30 2000-03-09 Hydroxymatairesinol in cancer prevention

Publications (2)

Publication Number Publication Date
DE60001271D1 DE60001271D1 (de) 2003-02-27
DE60001271T2 true DE60001271T2 (de) 2003-07-31

Family

ID=23075932

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60001271T Expired - Lifetime DE60001271T2 (de) 1999-03-30 2000-03-09 Hydroxymatairesinol in der krebs-prevention

Country Status (25)

Country Link
US (2) US6451849B1 (de)
EP (1) EP1165537B1 (de)
JP (2) JP4852685B2 (de)
KR (2) KR100741724B1 (de)
CN (1) CN1146553C (de)
AT (1) ATE231500T1 (de)
AU (1) AU767691B2 (de)
BG (1) BG65380B1 (de)
BR (1) BR0007187A (de)
CA (2) CA2650297C (de)
CZ (2) CZ301725B6 (de)
DE (1) DE60001271T2 (de)
DK (1) DK1165537T3 (de)
EE (1) EE200100507A (de)
ES (1) ES2189738T3 (de)
HK (1) HK1045992B (de)
HU (1) HUP0200530A3 (de)
MX (1) MXPA01009714A (de)
NO (4) NO330135B1 (de)
NZ (1) NZ512099A (de)
PL (1) PL199892B1 (de)
RU (1) RU2241453C2 (de)
SK (2) SK287001B6 (de)
WO (1) WO2000059946A1 (de)
ZA (1) ZA200104440B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271257B1 (en) * 2000-04-17 2001-08-07 Hormos Nutraceutical Oy Ltd. Decreasing the intracellular level of β-catenin by administering hydroxymatairesinol
WO2002034277A1 (en) * 2000-10-23 2002-05-02 Council Of Scientific And Industrial Research Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
JP2005500532A (ja) * 2001-08-16 2005-01-06 アナライザ， インコーポレーテッド 溶解度を測定するための方法
US7968350B2 (en) * 2001-11-12 2011-06-28 Analiza, Inc. Characterization of molecules
FI111638B (fi) * 2001-11-23 2003-08-29 Hormos Nutraceutical Oy Ltd Menetelmä hydroksimatairesinolin tuottamiseksi puusta
US7008666B2 (en) * 2001-11-26 2006-03-07 Hormos Nutraceutical Oy Ltd. Method of inhibiting overactivity of phagocytes or lymphocytes in an individual
US20030144216A1 (en) * 2002-01-25 2003-07-31 Mikko Unkila Method for prevention of diseases in coeliac patients
EP1472206A1 (de) * 2002-02-05 2004-11-03 Hormos Medical Corporation Lignanderivate
US7048960B2 (en) * 2002-03-22 2006-05-23 Glenn Roy Pizzey High lignan flaxseed product and product by process
FI20021184A (fi) 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita
FI114917B (fi) * 2002-08-29 2005-01-31 Hormos Nutraceutical Oy Ltd Lignaanikomplekseja
FR2851919A1 (fr) * 2003-03-03 2004-09-10 Lmd Lignanes utilisables comme inhibiteurs de cathepsines et leurs applications
US8099242B2 (en) 2003-06-12 2012-01-17 Analiza, Inc. Systems and methods for characterization of molecules
FI116727B (sv) 2003-11-12 2006-02-15 Arbonova Ab Oy Ny användning för kvistnötsextrakt
US7976877B2 (en) 2003-11-12 2011-07-12 Oy Arbonova Ab Use of knotwood extracts
US20070117864A1 (en) * 2003-12-26 2007-05-24 Tokyo University Of Agr. & Tech. Tlo Co., Ltd. Composition for preventing and treating hepatoma
WO2005074905A1 (ja) * 2004-02-03 2005-08-18 Kotosugi Inc. 雲南紅豆杉由来イソタキシレシノールを成分とする骨粗しょう症治療・予防薬
US20080057140A1 (en) * 2005-01-10 2008-03-06 Mikko Unkila Use of a Lignan for the Manufacture of a Composition for Preventing or Alleviating of Symptoms Relating to Estrogen Deficiency
US7595078B2 (en) * 2005-03-15 2009-09-29 Glanbia Nutritionals Ireland Limited Methods of increasing flaxseed hull recovery and resultant flax products
KR20080080390A (ko) 2005-12-19 2008-09-03 애널라이자, 인크. 스펙트럼 생체마커와 같은 데이터 패턴과 관련된 시스템 및방법
DE102006008772A1 (de) * 2006-02-22 2007-08-23 Beiersdorf Ag Hydroxymatairesinol gegen trockene Haut
DE102006019044A1 (de) * 2006-04-25 2007-10-31 Merck Patent Gmbh Antioxidantien
FI20106293A0 (fi) * 2010-12-06 2010-12-06 Emilia Peuhu Uudet farmaseuttiset koostumukset
EP2517574B1 (de) 2011-04-29 2015-11-11 Symrise AG Bestimmte Vanillyllignane und deren Verwendung als Geschmacksverbesserer
US10613087B2 (en) 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
RU2510268C1 (ru) * 2012-11-14 2014-03-27 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "Медресурс" Средство для лечения эстрогензависимых опухолей
KR20170002392A (ko) 2014-05-15 2017-01-06 리니아 에스.에이. 7-하이드록시마타이레시놀을 포함하는 조성물
US9678076B2 (en) 2014-06-24 2017-06-13 Analiza, Inc. Methods and devices for determining a disease state
CZ305794B6 (cs) * 2015-04-20 2016-03-16 Výzkumný ústav potravinářský Praha, v.v.i. Způsob úpravy dřevních suků s přesně regulovanou strukturou drtě pro výrobu lignanů a zařízení k provádění tohoto způsobu, s využitím v potravinářské výrobě
US9669006B2 (en) 2015-07-28 2017-06-06 U.S. Nutraceuticals, LLC Composition and method to treat and alleviate symptoms of hot flashes in a female subject
WO2017098089A1 (en) * 2015-12-09 2017-06-15 Granula Ab Ltd The use of a composition for lowering cholesterol level in a mammal, a method for its preparation, a composition and a method for preparing food additive comprising said composition
IT201700050994A1 (it) 2017-05-11 2018-11-11 Linnea Sa Uso di una Composizione comprendente 7-Idrossimatairesinolo
CA3236536A1 (en) 2021-10-28 2023-05-04 Arnon Chait Partitioning systems and methods for determining multiple types of cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628228D0 (en) * 1986-11-26 1986-12-31 Inst Biolog Morya Dalnevostoch Composition inhibiting pathological addiction to alcohol
US4808674A (en) * 1987-08-24 1989-02-28 General Electric Company Aryl ester-grafted polyphenylene ethers and phenylene ether-amide graft copolymers prepared therefrom
DE4317466A1 (de) 1993-05-26 1994-12-01 Degussa Verbessertes Verfahren zur Bleiche von Holzstoffen
WO1997014670A1 (en) 1995-10-18 1997-04-24 Kanoldt Arzneimittel Gmbh Lignans, a process for their production and pharmaceutical compositions and uses thereof
AU2100997A (en) 1996-03-08 1997-09-22 Energiser Plc Composition containing iso-flavonoids and lignans
CA2201652C (en) 1996-04-04 2007-09-11 The University Of Saskatchewan Use of purified sdg as an antioxidant
JP2987365B1 (ja) * 1998-10-29 1999-12-06 かどや製油株式会社 抗酸化剤
US20070117864A1 (en) * 2003-12-26 2007-05-24 Tokyo University Of Agr. & Tech. Tlo Co., Ltd. Composition for preventing and treating hepatoma

Also Published As

Publication number Publication date
CZ301725B6 (cs) 2010-06-02
HUP0200530A2 (hu) 2002-07-29
CN1345315A (zh) 2002-04-17
NO331188B1 (no) 2011-10-31
MXPA01009714A (es) 2003-06-24
EE200100507A (et) 2002-12-16
BG105856A (en) 2002-04-30
KR20070027770A (ko) 2007-03-09
RU2241453C2 (ru) 2004-12-10
CA2650297C (en) 2012-05-15
KR100741724B1 (ko) 2007-07-23
PL199892B1 (pl) 2008-11-28
ZA200104440B (en) 2002-07-30
ES2189738T3 (es) 2003-07-16
AU3169200A (en) 2000-10-23
KR20010108434A (ko) 2001-12-07
HK1045992A1 (en) 2002-12-20
CA2371839C (en) 2011-10-04
SK287749B6 (sk) 2011-08-04
NO20014639D0 (no) 2001-09-25
ATE231500T1 (de) 2003-02-15
CA2650297A1 (en) 2000-10-12
US6451849B1 (en) 2002-09-17
SK13262001A3 (sk) 2002-02-05
JP2002541158A (ja) 2002-12-03
NZ512099A (en) 2004-01-30
NO330135B1 (no) 2011-02-21
CZ20013486A3 (cs) 2002-02-13
KR100741723B1 (ko) 2007-07-23
DE60001271D1 (de) 2003-02-27
BG65380B1 (bg) 2008-05-30
HK1045992B (zh) 2005-02-25
WO2000059946A1 (en) 2000-10-12
SK287001B6 (sk) 2009-09-07
HUP0200530A3 (en) 2002-10-28
NO332251B1 (no) 2012-08-06
WO2000059946A8 (en) 2001-01-25
EP1165537A1 (de) 2002-01-02
NO332110B1 (no) 2012-06-25
US20010016590A1 (en) 2001-08-23
EP1165537B1 (de) 2003-01-22
PL350367A1 (en) 2002-12-02
CZ302730B6 (cs) 2011-10-05
BR0007187A (pt) 2002-02-19
NO20111291L (no) 2001-09-25
NO20014639L (no) 2001-09-25
JP2011052024A (ja) 2011-03-17
CN1146553C (zh) 2004-04-21
JP4852685B2 (ja) 2012-01-11
DK1165537T3 (da) 2003-05-12
AU767691B2 (en) 2003-11-20
NO20101067L (no) 2001-09-25
NO20101701L (no) 2001-09-25
CA2371839A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
ATE231500T1 (de) Hydroxymatairesinol in der krebs-prevention
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
BR9811121A (pt) Produto, composição farmacêutica, e uso de um produto
WO2001036640A3 (en) Human fgf-21 gene and gene expression products
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
WO2001076638A3 (en) Compositions for drug delivery
BR0110837A (pt) Quimioterapia de combinação
PT1150703E (pt) Terapia de esclerose multipla com chaperonina 10 e beta-interferao
MY103498A (en) Dl-5-[(2-benzyl-3, 4-dihydro-2h-benzopyran-6-yl)methyl] thiazolidine-2, 4-dione as an anti-atherosclerosis agent
ATE380555T1 (de) Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng
ZA200300675B (en) Pharmaceutical preparation of the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma.
IT1277118B1 (it) Composizioni farmaceutiche per il trattamento delle epatopatie croniche
RU95120677A (ru) Способ лечения злокачественных опухолей
NZ517348A (en) Use of a mycobacterial extract in the treatment of inflammatory bowel disease
MD1780G2 (ro) Metodă de tratament al pacienţilor cu ciroze hepatice
UA28489A (uk) Спосіб лікування затримки статевого розвитку у хлопцівпідлітків
PT1165596E (pt) Derivados de 14,15-alfa-metileno equilenina processos para producao dos mesmos e medicamentos que os contem
ZA991068B (en) Novel disubstituted naphthyl derivatives, their preparation, pharmaceutical compositions which contain them and their use for the preparation of medicinal products.
UA29106A (uk) Спосіб лікування вібраційної хвороби
WO2001035811A3 (en) Methods of diagnosing and determining prognosis of breast cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition